Otmane BOURZIKAT

Mr. Otmane BOURZIKAT

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
OBOtmane BOURZIKAT
Otmane BOURZIKAT
AAABDELMOULA EL ABBOUCHI
ABDELMOULA EL ABBOUCHI
HGHamza Ghammaz
Hamza Ghammaz
NBNabil EL BRAHMI
Nabil EL BRAHMI
EFElmostafa El Fahime
Elmostafa El Fahime
SKSaïd El Kazzouli
Saïd El Kazzouli
In the present study, new 2-phenyl-5,6,7,8-tetrahydroimidazo [1,2-b]pyridazines bearing sulfonamides were synthesized, characterized and evaluated for their anticancer activities. The structures of these derivatives were elucidated by 1H NMR, 13C NMR, infrared and high-resolution mass spectrometry for further validation of the target compound structures. The anticancer activities of the new molecules were evaluated against five human cancer cell lines, including A-549, Hs-683, MCF-7, SK-MEL-28 and B16-F10 cell lines using 5-fluorouracil and etoposide as the reference drugs. Among the tested compounds, 4e and 4f exhibited excellent activities in the same range of the positive controls, 5-fluorouracil and etoposide, against MCF-7 and SK-MEL-28 cancer cell lines, with IC50 values ranging from 1 to 10 μM. The molecular docking studies of 4e and 4f showed a strong binding with some kinases, which are linked to MCF-7 and SK-MEL-28 cancer cell lines.

29 December 2024 in Molecules
Verified
Journal Article
Open access
PDF file
ESEvan Saillard
Evan Saillard
OBOtmane BOURZIKAT
Otmane BOURZIKAT
KAKoffi Assa
Koffi Assa
VRVincent Roy
Vincent Roy
Luigi AgrofoglioLuigi Agrofoglio
Luigi Agrofoglio
The emergence of RNA viruses driven by global population growth and international trade highlights the urgent need for effective antiviral agents that can inhibit viral replication. Nucleoside analogs, which mimic natural nucleotides, have shown promise in targeting RNA-dependent RNA polymerases (RdRps). Starting from protected 5-iodouridine, we report the synthesis of hitherto unknown C5-substituted-(1,3-diyne)-uridines nucleosides and their phosphoramidate prodrugs. The modifications at C5 include 4-(trifluoromethyl)benzene (a), 4-pentyl-benzene (b), 3,5-dimethoxy-benzene (c), 4-(trifluoromethoxy)benzene (d), 3-aniline (e), 4-pyridine (f), 3-thiophene (g), C6H13 (h), 2-pyrimidine (i), cyclopropyl (j), and phenyl (k) groups. These compounds were synthesized using Sonogashira palladium-catalyzed reactions and nickel–copper-catalyzed C-H activation between various alkynes, yielding between 25% and 67%. The antiviral activities of obtained compounds were measured through HTS against RNA viruses including influenza H1N1 and H3N2, human respiratory syncytial virus (RSV), SARS-CoV-2, Zika, hepatitis C virus (HCV), Hepatitis E virus (HEV), as well as against coronavirus (HCoV-229E). Unfortunately, none of them showed promising antiviral activity, with less than 85% inhibition observed in the cell viability screening of infected cells.

7 April 2026
Verified
Thesis
Closed access
OBOtmane BOURZIKAT
Otmane BOURZIKAT
La protéine kinase BRAF est une sérine/thréonine kinase, qui joue un rôle primordial dans la transduction des signaux permettant la prolifération et la survie cellulaire. Les mutations provoquent une suractivation de BRAF, ce qui peut se traduire par plusieurs types de cancers. Ce manuscrit est essentiellement dédié à la synthèse de nouveaux inhibiteurs de BRAF. Dans une première partie, nous avons synthétisé deux séries originales de molécules non-fluorescentes à base des noyaux isoindolin-1[2H]-one et isoquinolin-1[2H]-one. Dans une deuxième partie, nous avons développé deux types de molécules fluorescentes potentiellement actives sur BRAF, des complexes isoindolinones-difluorure de bore, ainsi que des triazapentalènes tétracycliques. Du point de vue spectroscopique, l'ensemble des résultats obtenus montrent que les fluorophores synthétisés présentent de bonnes propriétés de fluorescence. A l'issue des tests biologiques réalisés sur les composés synthétisés ainsi que quelques produits de références, nous avons obtenu pour certaines molécules d'excellentes activités enzymatiques sur BRAF sauvage et BRAF mutée [Kd= 0,42-43 nM] et ce, avec une forte sélectivité. De bons résultats de cytotoxicité ont également été enregistrés. A noter que pour parachever le travail, nous avons réalisé des expériences de co-cristallisation de certains de nos inhibiteurs au sein de site actif de la kinase BRAF.